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Abstract
An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus meeting of expert
panellists met on 15 January 2014 to review current evidence on the management of intrahepatic
cholangiocarcinoma (ICC) in order to establish practice guidelines and to agree on consensus state-
ments. The treatment of ICC requires a coordinated, multidisciplinary approach to optimize survival.
Biopsy is not necessary if the surgeon suspects ICC and is planning curative resection, although
biopsy should be obtained before systemic or locoregional therapies are initiated. Assessment of
resectability is best accomplished using cross-sectional imaging [computed tomography (CT) or
magnetic resonance imaging (MRI)], but the role of positron emission tomography (PET) is unclear.
Resectability in ICC is defined by the ability to completely remove the disease while leaving an
adequate liver remnant. Extrahepatic disease, multiple bilobar or multicentric tumours, and lymph
node metastases beyond the primary echelon are contraindications to resection. Regional lympha-
denectomy should be considered a standard part of surgical therapy. In patients with high-risk
features, the routine use of diagnostic laparoscopy is recommended. The preoperative diagnosis of
combined hepatocellular carcinoma and cholangiocarcinoma (cHCC–CC) by imaging studies is
extremely difficult. Surgical resection remains the mainstay of treatment, but survival is worse than in
HCC alone. There are no adequately powered, randomized Phase III trials that can provide definitive
recommendations for adjuvant therapy for ICC. Patients with high-risk features (lymphovascular
invasion, multicentricity or satellitosis, large tumours) should be encouraged to enrol in clinical trials
and to consider adjuvant therapy. Cisplatin plus gemcitabine represents the standard-of-care, front-
line systemic therapy for metastatic ICC. Genomic analyses of biliary cancers support the development
of targeted therapeutic interventions.
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Diagnosis and staging of intrahepatic
cholangiocarcinoma
Clinical presentation
The clinical presentation of intrahepatic cholangiocarcinoma
(ICC) is often not specific and patients with early-stage disease
are usually asymptomatic. Patients may present with a wide
array of symptoms that include weight loss, malaise, abdominal
discomfort, hepatomegaly or a palpable abdominal mass in
more advanced stages.1 Biliary tract obstruction is relatively
infrequent among patients with ICC.
Pathologic features
Whereas the clinical suspicion of ICC can be based on a combi-
nation of clinical presentation, laboratory analyses and radio-
logic evaluation, pathologic evidence is required for a definitive
diagnosis. Although tissue biopsy is needed to confirm a histo-
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logic diagnosis, it is not routinely recommended or necessary in
all patients in whom surgery is planned. In fact, liver biopsy is
not routinely recommended or necessary for the surgeon to
proceed with resection; however, pathologic diagnosis is neces-
sary before systemic chemotherapy or radiation therapy can be
started. Although a liver biopsy can help to establish a diagno-
sis, a ‘negative’ biopsy does not exclude ICC given the potential
for sampling error. When a biopsy is performed, the most com-
mon histologic finding is adenocarcinoma with some associated
fibrous stroma. The histologic appearance of ICC can be com-
parable with that of metastatic adenocarcinoma arising from
other tumours of gastrointestinal or pancreatic origin. Most
often, the differentiation of ICC from metastatic adenocarci-
noma requires further immunohistochemical evaluation [e.g.
negative: lung (TTF1), colon (CDX2), pancreas (DPC4); posi-
tive: biliary epithelium (AE1/AE3; CK7+ and CK 20)]. Differen-
tiation between ICC and mixed hepatocellular tumours may
require further evaluation of specific markers of hepatocellular
or progenitor cell features (e.g. Hep-Par-1, GPC3, HSP70,
EpCAM, etc.), although this distinction is difficult on biopsy
specimens.2 Plasma serum markers for ICC tend to have high
specificity, but low sensitivity. For example, carbohydrate anti-
gen (CA) 19-9 is elevated in only about 50% of ICC cases,
whereas carcinoembryonic antigen (CEA) is elevated in 15–20%
of cases.1–3 As such, these markers are not sufficiently sensitive
to definitively rule out ICC when they are within normal limits.
Extent of preoperative evaluation
When a biopsy reveals unspecified adenocarcinoma and the
lesion is radiographically indeterminate of a primary ICC, as
opposed to metastatic disease, the diagnostic work-up should
include a search for the potential primary tumour. This evalua-
tion may include cross-sectional imaging of the chest, abdo-
men and pelvis, and colonoscopy and upper endoscopy should
be strongly considered to rule out a primary gastrointestinal
tumour. In the setting of portal or coeliac adenopathy, an
endoscopic ultrasound (EUS) with nodal sampling may also be
helpful to define whether disease exists in the nodal basins.4,5
A mammogram should also be performed in women, as well
as appropriate gynaecologic evaluation.
By contrast, when biopsy (with immunohistochemical stain-
ing) and imaging strongly support the diagnosis of ICC, the
additional work-up for a primary tumour described above may
not be necessary as it is likely to yield very little information
and obtaining these tests prolongs the time until definitive
treatment can be completed.
Imaging characteristics of ICC
On ultrasonography, ICC typically appears as a hypoechoic
mass and may be associated with peripheral ductal dilatation,
although these features are not specific. Hyperenhancement on
contrast-enhanced ultrasound can identify tumours with an
increased density of cancer cells, but lacks specificity for ICC.6
Intrahepatic cholangiocarcinoma may be incidentally detected
by cross-sectional imaging performed for other reasons. On
computed tomography (CT), the typical appearance is that of
a hypodense hepatic mass with irregular margins in the unen-
hanced phase, peripheral rim enhancement in the arterial
phase, and progressive hyperattentuation on venous and
delayed phases.7 Computed tomography can show the presence
of capsular retraction indicating hepatic atrophy. Intrahepatic
cholangiocarcinoma is most often characterized by a progres-
sive contrast uptake from the arterial to the venous phase, with
increased uptake in the delayed phase. This finding may reflect
fibrosis that is slow to enhance but retains the intravenous
contrast agent. On magnetic resonance imaging (MRI), ICC
typically appears hypointense on T1-weighted and hyperintense
on T2-weighted images; T2-weighted images may also show
central hypointensity corresponding to areas of fibrosis.8
Dynamic images show peripheral enhancement in the arterial
phase followed by progressive and concentric filling in of the
tumour with contrast material. Pooling of contrast on delayed
images is indicative of fibrosis and suggestive of ICC in the
right clinical setting.9 Magnetic resonance imaging with cho-
langiopancreatography (MRI/MRCP) can be helpful in visualiz-
ing the ductal system and vascular structures and thereby
determining the anatomic extent of tumour.
Up to 80–90% of ICCs will be avid on fluorodeoxyglucose
positron emission tomography (FDG-PET). Although PET can
detect mass-forming ICCs with relatively high sensitivity, it is less
useful for infiltrating ICC tumours. The clinical utility of
PET-CT for diagnosis of ICC when CT or MRI has already been
performed is controversial. In the absence of suspicious disease
outside the liver on CT or MRI, some investigators have ques-
tioned the additional utility of PET.10,11 Some small studies have,
however, suggested that the use of FDG-PET may result in the
identification of occult metastatic disease in up to 20–30% of
patients and may even help to rule out an occult primary
tumour.10,12
Staging
Traditionally, until the publication of the current 7th edition
of the American Joint Committee on Cancer/International
Union against Cancer (AJCC/UICC) staging manual, there was
no distinct staging system for ICC. Rather, ICC was staged
according to the criteria derived from patients with hepatocel-
lular cancer (HCC). Given the epidemiologic and biologic dif-
ferences between ICC and HCC, there has been increasing
realization of the importance of establishing a distinct staging
system for ICC. The 7th edition of the AJCC/UICC staging
manual largely reflects many of the proposals included in
previous publications. Tumour size is no longer a prognostic
factor; rather, T-classification is based on number of lesions,
vascular invasion, intrahepatic metastasis and invasion of adja-
cent structures. Specifically, T1 tumours are solitary without
vascular invasion; T2 disease includes multiple tumours (e.g.
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multifocal disease, satellitosis, intrahepatic metastasis), as well
as tumours associated with any type of vascular invasion (e.g.
microvascular or major vascular invasion); T3 tumours directly
invade adjacent structures, and T4 disease includes tumours
with any periductal infiltrating component (Fig. 1). As with
most other solid liver/biliary/gastrointestinal malignancies,
AJCC/UICC staging also includes both an ‘N’ and an ‘M’ sub-
classification. Regional lymph node (LN) metastases in the
hilar, periduodenal and peripancreatic nodes are considered
N1 disease, whereas distant disease is considered M1 disease.13
Although the 7th edition of the AJCC/UICC manual is still
relatively new, the validity of the staging system has been inde-
pendently validated.14 The 7th edition of the AJCC/UICC stag-
ing system for ICC was noted to be more discriminating in
predicting survival than other staging systems.15 Furthermore,
patients were equally distributed among the AJCC/UICC 7th
edition stages, which was not the case for the other staging sys-
tems studied. There are, however, undoubtedly limitations to
the current 7th edition staging system for ICC. For example,
multiple tumours are classified as representing stage T2b. From
a clinical standpoint, it is difficult to distinguish among
patients with ‘multiple’ tumours who have multifocal disease
and those with an index lesion and intrahepatic metastases or
satellite lesions. In addition, the impact of size on prognosis
may be more nuanced and have a non-linear threshold effect.
In a recent study, the effect of tumour size on risk for death
was linear until the tumour reached a diameter of approxi-
mately 7 cm, after which the risk for death associated with fur-
ther incremental increase in size plateaued.16 Finally, the
classification of T4 disease as any tumour with periductal infil-
tration requires further validation in future studies that specifi-
cally examine the impact of this prognostic factor.
Consensus statements
• Tumour markers are insufficient to make a diagnosis or rule
out ICC.
• Biopsy is not necessary if the surgeon suspects ICC and is
planning curative resection. Biopsy should be obtained before
systemic or locoregional therapies are initiated in order to
confirm the diagnosis in the setting of unresectable disease.
When biopsy is obtained, immunostains are required to dif-
ferentiate ICC from other possible metastatic lesions, as well
as to differentiate ICC from mixed hepatocellular tumours.
• In the setting of a liver mass with a biopsy showing adeno-
carcinoma, an occult primary tumour should be ruled out in
most instances, unless immunohistochemical staining and
imaging are clearly consistent with ICC.
• Assessment of resectability and/or intra- and extrahepatic
metastatic disease, as well as venous and arterial invasion, is
best accomplished using radiographic studies such as CT
and/or MRI.
• In view of the limited data, the role of PET for staging ICC
is unclear and thus PET should be used selectively.
• The 7th edition of the AJCC/UICC ICC staging schema is
the preferred staging system for ICC.
Surgical treatment of ICC
Many locoregional treatment modalities are available for
patients with ICC. Unfortunately, most modalities, including
ablation and hepatic intra-arterial therapies, have marginal
therapeutic roles as a result of inherent limitations and/
or the lack of a durable tumour response.1 Therefore, surgi-
cal resection, as the only potentially curative treatment,
remains the mainstay of therapy for patients with resectable
disease.
Definition of resectability
Potentially resectable tumours include those that can be com-
pletely extirpated with negative histologic margins while a suf-
ficient liver remnant is retained (i.e. a minimum of two
contiguous segments with adequate perfusion, and venous and
biliary drainage).17–19 The presence of extrahepatic disease,
including the involvement of LNs beyond the regional basin13
(i.e. N2 nodes such as the coeliac and the para-aortic nodes),
is a contraindication to resection.
Similarly, in patients with bilateral multifocal or multicentric
disease, resection should be avoided. In fact, several studies
have shown that multiplicity of tumours, a feature reported in
up to 44% of patients,3,17,18,20,21 portends a shorter period of
survival as reflected in the tumour–node–metastasis (TNM)
staging (i.e. T2 tumour).13 It is currently less well understood
whether satellite nodules, synchronous multicentric tumours
and bilateral intrahepatic metastases, all of which are usually
classified into the broad category of ‘multiple tumours’, have
different natural histories. Theoretically, the worst prognosis
may be associated with bilateral multifocal disease22 because it
is likely to represent systemic haematogenous metastatic intra-
hepatic dissemination, although there are no data to address
the prognostic relevance of true peritumoral satellite lesions
versus multifocal disease. Based on this definition of resectabil-
ity, even patients with advanced complex tumours that will
require extensive resections and major vascular and biliary
reconstruction should be considered as potential candidates for
resection.23,24 Negative-margin (R0) resection rates can
approach 85% with an aggressive surgical approach that often
involves a major or extended hepatectomy (in up to 70% of
cases) or a concomitant bile duct or vascular resection (in up
to 20% and 5% of cases, respectively).17
With proper patient selection, rates of 5-year survival fol-
lowing resection range from 30% to 40%.17,23,25,26 Recently, a
large multi-institution series of 301 patients demonstrated that
more than half of the patients experienced recurrence after
resection and, in most instances (61%), this was within the
liver.19 The optimal treatment of recurrent disease is unclear,
as is the issue of whether these patients should be considered
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Figure 1 American Joint Committee on Cancer 7th edition staging system for intrahepatic cholangiocarcinoma
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for repeat liver resection. Few studies have evaluated the
impact of repeat hepatectomy, but some have suggested a sur-
vival benefit for highly selected patients who are considered to
be eligible for repeat resection.20,27,28 There are no studies that
compare systemic, regional or local treatment strategies with
repeat resection. Clearly, further studies are necessary to eluci-
date the ideal treatment of liver-only recurrent disease, which
is a common pattern in ICC.
Prognostic factors following resection
Longterm survival after surgery is dependent on several factors.
The majority of studies have identified completeness of
resection (R0), number of tumours (single versus multiple),
presence of vascular invasion and LN metastases as the most
important determinants of prognosis.3,17,18,21,25,26,29 In particu-
lar, multiple reports have indicated the presence of LN metas-
tases as the most important independent predictor of
survival.17,18,21,25,26,29 Attesting to the impact of nodal disease,
margin status is not predictive of outcome in the setting of LN
involvement.3
Role of lymphadenectomy
The role of routine lymphadenectomy is still controversial,
especially in the West. Recent data from the National Cancer
Institute’s Surveillance, Epidemiology and End Results (SEER)
registry show that only 55% of patients have pathologic evalu-
ation of at least one regional LN,18,25 despite the fact that
LN metastasis is universally cited as a negative prognostic
factor.3,17,18,25 In addition, the incidence of nodal disease is
high, with some studies showing LN metastasis in as many as
40% of patients.3,17,18,25 Because of its prognostic relevance
and high incidence, many authors have argued in favour of
including this procedure as a standard approach in all patients
undergoing hepatectomy for ICC, although prospective trials
have not addressed this issue.1,17,18,25 Longterm survival is rare
but possible even in the setting of LN metastasis,29,30 although
admittedly these longterm survivors are likely to be patients
with occult nodal disease rather than grossly positive regional
nodes on cross-sectional imaging. In addition to the essential
role of lymphadenectomy for accurate staging, which, in turn,
may assist in decision making regarding adjuvant therapy,
some authors have suggested a therapeutic benefit in decreas-
ing locoregional recurrence.30,31 Based on the existing data for
ICC, and on more developed data for many other tumour
types including breast and melanoma, it is possible that lym-
phadenectomy improves staging and prognosis, but the role of
lymphadenectomy in decreasing locoregional recurrence
remains unclear. Because of the poor outcome in patients with
nodal disease, in whom median survival is 7–14 months,18,32
the best initial treatment for patients with grossly positive
porta hepatis LNs is systemic chemotherapy, followed by
restaging to assure no progression of disease, prior to any
contemplation of resection.
Technical issues regarding lymphadenectomy
The ideal lymphadenectomy should include all regional nodal
stations. Clinical and pathologic data indicate that LNs of the
hepatoduodenal ligament and the hepatic artery are the first to
become involved in the metastatic process and should be
removed in all patients.13 For ICC originating in the right hemi-
liver, the retropancreatic LNs, which are still considered as first
echelon nodes, may be involved;13 as a consequence, their rou-
tine removal is recommended. Another direct lymphatic path-
way is recognized as running from the left hemiliver to the
stomach through the lesser omentum.33 Therefore, in patients
with ICC originating from the left hemiliver, the nodes around
the cardiac portion of the stomach and along the lesser curva-
ture have a higher likelihood of involvement and thus should
also be removed for adequate lymphadenectomy.13
At present, there is no specific evidence for the minimum
number of LNs required to facilitate accurate staging.
Complicating this discussion, the number of nodes retrieved is
likely to vary according to age, anatomy, and the thoroughness
and method of pathologic examination of the specimen.34
Staging laparoscopy
The yield of staging laparoscopy in patients with ICC varies from
27% to 38%.13,26,35 Two prospective studies36,37 found staging
laparoscopy precluded resection in 25–36% of patients as a result
of findings of occult metastatic disease. Therefore, a substantial
number of unresectable patients will benefit from staging laparos-
copy, the costs of which are acceptable and which incurs only a
moderate increase in operative time in patients with presumed
resectable disease.37 Thus, staging laparoscopy should be rou-
tinely utilized in high-risk patients (i.e. patients with multicentric
disease, high CA 19-9, questionable vascular invasion or suspicion
of peritoneal disease) because of the risk that occult metastatic
disease will be discovered at the time of surgery. Use of laparo-
scopic ultrasonography may further increase the utility of staging
laparoscopy because unresectability may reflect intrahepatic
metastases or extensive vascular invasion that can only be assessed
with ultrasound. Therefore, in selected high-risk patients, use of
laparoscopic ultrasonography is also recommended.
Consensus statements
• Resectability for ICC is defined by the ability to completely
remove the disease with curative intent (R0) while leaving
an adequate liver remnant. Extrahepatic disease, multiple
bilobar or multicentric tumours, and LN metastases beyond
the primary echelon are formal contraindications to resec-
tion.
• Regional lymphadenectomy should be considered a standard
part of surgical therapy for patients undergoing resection of
ICC.
• For patients with high-risk features, the routine use of diag-
nostic laparoscopy with selective use of laparoscopic ultraso-
nography is recommended.
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Combined hepatocellular carcinoma and
cholangiocarcinoma
Combined hepatocellular carcinoma and cholangiocarcinoma
(cHCC–CC) is a rare primary cancer in which dual differentia-
tion toward hepatocytes and bile duct epithelia coexists in the
same tumour or in the same liver. Combined HCC–CC was
first described by Wells in 1903, and classified into three cate-
gories by Allen and Lisa in 1949.38 It was further classified by
Goodman et al. in 1985.39
Aetiology
The most common primary liver cancer is HCC, which
accounts for more than 90% of all primary hepatic malig-
nancies. The second most frequent is ICC, which accounts
for 5–10% of cases. The incidence of cHCC–CC has been
reported to range from 0.7% to 14.0% in clinical and
autopsy cases.39–42 Reports from Asian countries have shown
that 60–70% of patients with cHCC–CC have hepatitis C or
B virus and 54–73% have cirrhotic livers.43,44 However, in a
Western report, the incidence of hepatitis virus infection was
15% and no cirrhosis was found in 27 patients.45 Because of
the rarity of this tumour, there has been no large-scale inves-
tigation of the risk factors for development of cHCC–CC;
however, conditions commonly found in patients with HCC
or ICC, such as cirrhosis, hepatitis virus infection, alcoholic
liver disease and metabolic syndrome, are common in
cHCC–CC.
A recent SEER study evaluating incidence over three decades
found no difference in the incidence of cHCC–CC over time.
Overall, cHCC–CC accounted for 0.87% of all liver tumours.46
Although there was no difference in incidence, there did
appear to be an improvement in outcome over time.46
Pathology and classification of cHCC–CC
Allen and Lisa classified cHCC–CC into types based on its his-
tologic features.38 They proposed three types of cHCC–CC: in
type A, HCC and CC are present at different sites within the
same liver; in type B, HCC and CC are present at adjacent sites
and mingle with continued growth, and in type C, HCC and
CC are combined within the same tumour.
Goodman et al.39 proposed a new classification involving
three types: type I involves ‘collision tumours’ that contain
two distinct or merging nodules with separate histologies of
HCC and ICC; type II involves ‘transitional tumours’ that
exhibit distinct HCC- and ICC-like areas, each of which also
contain intermediate features and transition from one morpho-
logic phenotype to another, and type III, in which ‘fibrolamel-
lar tumours’ exhibit a combination of HCC and ICC
differentiation throughout the tumour, with crypts and
pseudocrypts of excretion mucus and without separate areas of
one or the other. Clinically, type I and II tumours are more
like HCC than ICC.
In a strict sense, true cHCC–CC are thought to be tumours
corresponding to type C of Allen and Lisa38 and type II of
Goodman et al.,39 in which the morphologies of HCC and CC,
respectively, are distinct but are intermingled within the
tumour.40,41,43–45,47 The World Health Organization (WHO)
classification describes cHCC–CC as a tumour containing
unequivocal, intimately mixed elements of both HCC and CC.
This tumour should be distinguished from separate HCC and
CC arising in the same liver. Such tumours may be separated
or intermixed (‘collision tumour’).48
Symptoms
The symptomatology of cHCC–CC is similar to that of HCC
or ICC in that most patients will have no specific symptoms.
In advanced stages, patients may experience abdominal pain,
weight loss or general fatigue. Patients with tumours involving
the hepatic hilum may present with obstructive jaundice, simi-
larly to patients with hilar cholangiocarcinoma.
Diagnosis
Preoperative diagnosis of cHCC–CC can be made in only a
minority of cases because of both the complex imaging features
of the two entities and the rarity of this tumour.49 The imag-
ing characteristics of cHCC–CC include not only features typi-
cal of HCC, such as arterial enhancement, washout and
pseudocapsule, but also features typical of ICC, such as an
irregular tumour surface, peripheral arterial enhancement or
late central enhancement.
The tumour markers, a-fetoprotein (AFP), protein induced
by vitamin K absence or antagonists-II (PIVKA-II), CEA and
CA 19-9, are useful in making the diagnosis of cHCC–CC. Dis-
cordance between tumour marker elevation and imaging mor-
phology may be suggestive of cHCC–CC.45 For instance, in a
tumour with the imaging features of HCC, but with elevated
serum CA 19-9, suspicion for cHCC–CC should be increased.
Unfortunately, no studies have evaluated the sensitivity and
specificity of tumour markers to assess tumour histology in
patients with cHCC–CC.
Surgical treatment
Hepatic resection
Surgical resection remains the only curative option for
patients with cHCC–CC. Resection of cHCC–CC involves
hepatectomy, which is occasionally combined with resection
of the extrahepatic bile duct and/or portal vein in order to
achieve an R0 resection. Preoperative portal vein emboliza-
tion is necessary in patients with a small future liver rem-
nant (FLR) volume to increase the safety of major
hepatectomy.
The role of lymphadenectomy is unclear. The incidence of
nodal metastases varies and these data are limited based on
the small patient numbers reported. Yin et al.41 reported that
the incidence of nodal metastasis in 103 patients with
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cHCC–CC was 13.2%, which was higher than that in 6679
patients with HCC (2.1%) and lower than that in 386
patients with ICC (21.4%). In a series from Italy, the inci-
dence of nodal metastasis was 44%, which was comparable
with that in ICC (36%).50 There are few data on the
prognostic importance of nodal disease in patients with
cHCC–CC. Because of the rarity of this tumour, there is no
definitive evidence available to elucidate the role of nodal
dissection, but it is likely that nodal staging will give
additional prognostic information.
Liver transplantation
Combined HCC–CC is considered a relative contraindication to
transplantation. A recent analysis of SEER data evaluated 3432
patients (3378 with HCC and 54 with cHCC–CC) submitted to
liver resection or liver transplantation for hepatic tumours.51
There was no difference in 3-year survival rates between
cHCC–CC patients submitted to liver transplantation and those
submitted to resection (48% and 46%, respectively; P = 0.56),
although no multivariate analysis was performed to control for
tumour stage or other prognostic factors. Median survival
following liver transplant for HCC was markedly improved
(68 months) in comparison with that in patients with cHCC–CC
(36 months), and this difference was sustained when other
factors including stage and tumour size were controlled [hazard
ratio (HR) for death in cHCC–CC patients compared with HCC
patients: 2.5, 95% confidence interval (CI) 1.2–5.1; P = 0.01].
Because of the scarcity of donor organs, and worse outcomes
following transplantation, cHCC–CC should remain a contrain-
dication to transplant. Improvements in the ability to accurately
preoperatively diagnose cHCC–CC, as opposed to HCC, are
necessary in order to direct patients to resection.
Comparison of prognoses after hepatectomy for
cHCC–CC, HCC and ICC
In several series, the survival of patients with cHCC–CC has
been noted to be worse than that of patients with HCC or
ICC.40,47 However, in other reports, the survival of patients
with cHCC–CC was intermediate in comparison with that in
HCC and ICC patients.4,6 In most reported series, however,
the survival of cHCC–CC patients is worse than that of HCC
patients (5-year survival rates: 8–36% versus 37–66%, respec-
tively).40,41,43,45
Conclusions
Combined HCC–CC is a rare hepatic cancer in which dual dif-
ferentiation toward hepatocytes and bile duct epithelia coexists
in the same tumour. The preoperative diagnosis of cHCC–CC
by imaging studies is difficult and the evaluation of tumour
markers may be helpful in identifying components of HCC or
ICC. Surgical resection remains the mainstay of treatment. The
survival of patients with cHCC–CC after hepatectomy is worse
than that in patients with HCC.
Consensus statements
• Combined HCC–CC is a rare primary cancer in which dual
differentiation toward hepatocytes and bile duct epithelia
coexists in the same tumour.
• The preoperative diagnosis of cHCC–CC by imaging studies
is extremely difficult. Evaluation of tumour markers may
help to identify the components of HCC or CC, but data to
evaluate the sensitivity and specificity of tumour marker
evaluation to assess tumour type are limited.
• Surgical resection remains the mainstay of definitive treat-
ment.
• The survival of patients with cHCC–CC after hepatectomy is
likely to be worse than that of patients with HCC, but
survival data are limited by small series and thus definitive
evidence on outcomes in HCC and ICC, respectively, are
lacking.
Adjuvant and systemic therapy for ICC
Intrahepatic cholangiocarcinoma is an uncommon entity, albeit
with a rising incidence, in part related to the hepatitis C epi-
demic.18,52,53 A recent review of the SEER database demon-
strated that there has been a 10-fold increase in
cholangiocarcinoma-related mortality since 1973.54 Treatment
recommendations in both the adjuvant and metastatic settings
are based on a paucity of Phase III trial data. Complicating this
further, most of these datasets include patients with gallbladder
disease, and extra- as well as intrahepatic cholangiocarcinoma,
and, in some cases, patients with ampullary cancer.
Adjuvant therapy
Evaluating patterns of failure is instructive in providing insight
regarding what might be the best approach to adjuvant
therapy. For ICC, by contrast with hilar and distal cholangio-
carcinoma, local/regional and intrahepatic failure are major
issues, and systemic failure is a secondary consideration.55,56
In fact, following resection, recurrence occurs in the liver in
50–60% of patients, in the peritoneum in about 20%, and in
the portal LNs in 20–30%.19,32,57 Thus, both locoregional
modalities and systemic therapy are valid options in the
adjuvant setting.
Regarding adjuvant radiation, most studies to date are lim-
ited in design, there have been no adequately powered pro-
spective randomized trials, and much of the insight derives
from single-institution prospective series.58 Most studies evalu-
ating radiation utilized external beam radiation with or with-
out brachytherapy. Studies have typically included a mix of
patients, among whom most patients have undergone an R0 or
R1 (positive margin) resection, but some have had an R2
resection. Additionally, trials have included both cholangiocar-
cinoma as well as gallbladder cancer patients. One small study
evaluated surgery versus surgery in combination with external
beam radiation therapy.59 Three-year survival rates of 10%
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(surgery) and 31% (chemoradiation) (P = 0.0005), respectively,
were observed in these two populations.59 Unfortunately, 90%
of patients in this series had a positive margin resection, which
brings into question the involvement of the resection margin
in these results. Demonstrating this point, a separate series
evaluated a similar adjuvant therapy strategy in margin-nega-
tive patients and observed no difference in median overall sur-
vival (18.4 months and 20.0 months, respectively).60 Thus, the
overall role of adjuvant radiation and which specific patient
populations it may benefit remain to be defined.
With regard to adjuvant systemic therapy, two randomized
trials have been conducted but were limited by the inclusion of
multiple tumour types, and thus were not adequately powered
to detect differences in ICC patients alone. One study evalu-
ated a regimen of surgery and 5-fluorouracil (5-FU)/mitomy-
cin followed by oral 5-FU in comparison with surgery alone in
patients with resected pancreas, bile duct, gallbladder and
ampullary cancers.61 In the 118 patients with bile duct cancer,
72 of whom underwent curative resection, there was no differ-
ence in overall survival between the groups (41% in the adju-
vant therapy group and 28% in the surgery-only group;
P = 0.48). More recently, the results of the European Study
Group for Pancreatic Cancer (ESPAC)-3 periampullary trial
were reported.62 In a preplanned subset analysis, no differences
in outcome were observed between the surgery-alone group
and the adjuvant treatment arm in patients with bile duct can-
cer (96 patients, 22% of enrolees).62
A systematic review and meta-analysis of adjuvant therapy
involving over 6000 patients in 20 studies, many of which
were retrospective, was recently published.63 There was a
non-statistically significant beneficial trend for adjuvant ther-
apy over observation (HR 0.75, 95% CI 0.55–1.01; P = 0.06).
Patients who received systemic therapy with or without the
addition of radiation therapy had greater benefit than those
who received radiation alone [odds ratio (OR) 0.39, 95% CI
0.39–0.98; P = 0.02]. The analyses also supported adjuvant
chemotherapy or chemoradiotherapy in positive-margin
resection (R1) (OR 0.36, 95% CI 0.19–0.68; P = 0.002) and
patients with LN metastasis (OR 0.49, 95% CI 0.3–0.8;
P = 0.004).
Three ongoing or recently completed studies will define pro-
spective data on the role of adjuvant therapy. The BILCAP
study evaluated capecitabine compared with observation
(NCT00363584) in 360 patients. The UNICANCER trial of 190
patients evaluated gemcitabine/oxaliplatin compared with
observation (NCT01313377), and a Japanese study (BCAP)
is evaluating gemcitabine compared with observation
(NCT000000820). In addition, in North America, the South-
western Oncology Group (SWOG) has recently completed a
single-arm, non-randomized Phase II study of four cycles of
adjuvant gemcitabine/capecitabine followed by capecitabine-
based external beam radiation in resected extrahepatic cholan-
giocarcinoma and gallbladder patients (NCT00789958). These
latter data may provide a contemporary reference arm for
future randomized controlled trials.
To summarize the existing adjuvant therapy data, there are
no definitive data to provide recommendations regarding the
optimal adjuvant therapy for patients with ICC. Current data
suggest that for patients with margin-positive and node-posi-
tive resected cholangiocarcinoma, systemic therapy with gem-
citabine or 5-FU, or 5-FU-based radiation should be
considered. There are insufficient data to guide recommenda-
tions for node-negative and margin-negative patients. For all
patients, when possible, enrolment in a clinical trial should be
strongly encouraged.
Metastatic cholangiocarcinoma
Similar to the situation in the adjuvant setting, most trials in
the context of advanced disease have typically included patients
with not only intra- and extrahepatic cholangiocarcinomas but
also gallbladder and ampullary cancers. Pooled analyses from
nearly 3000 patients included in 104 trials from 1985 to 2006
suggest that combination cytotoxic therapy has a role and that
gemcitabine and a platinum-based therapy is a reasonable
option.64 The Advanced Biliary Cancers (ABC)-02 randomized
Phase II–III trial provided concrete support for gemcitabine
and cisplatin, demonstrating improvements for the combina-
tion compared with gemcitabine alone both in overall survival
(11.7 months versus 8.1 months; P < 0.001) and in progres-
sion-free survival (8.0 months versus 5 months; P < 0.001).65
This trial included patients with intra- and extrahepatic cho-
langiocarcinoma, gallbladder and ampullary cancer, and
patients with both locally advanced and metastatic disease. In
the subset of bile duct cancer patients, benefits similar to the
results of the overall trial were observed. These results have led
to the use of gemcitabine and cisplatin as the standard of care
in patients with metastatic ICC. Multiple other cytotoxic
options have been studied, mostly in Phase II settings, suggest-
ing that other gemcitabine-based combinations and 5-FU-
based combinations also have value, although none have been
compared with cisplatin and gemcitabine.66
The genomics and molecular pathology of biliary cancers
have been increasingly defined and a broad spectrum of muta-
tions in tumour suppressor genes and oncogenes identified,
particularly in terms of the recent identification of IDH1
mutations in ICC. These observations have provided the
underpinnings of an evaluation of targeted therapy in this dis-
ease, with a particular focus on anti-angiogenic therapy and
disruption of the epidermal growth factor receptor (EGFR)
pathway.67–70 A South Korean Phase III study of 268 patients
evaluated the addition of erlotinib 100 mg daily to gemcita-
bine/oxaliplatin.71 For the primary endpoint of progression-
free survival, there was no statistically significant difference
between the chemotherapy-alone arm (4.2 months for gem/ox
versus 5.8 months for erlotinib/gem/ox; HR 0.80, 95% CI
0.51–1.03; P = 0.087). Patients with cholangiocarcinoma
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achieved progression-free survival of 3.0 months with chemo-
therapy alone compared with 5.9 months with chemotherapy
and erlotinib (HR 0.73, 95% CI 0.53–1.00; P = 0.049), sug-
gesting that there may be value in adding erlotinib in
advanced cholangiocarcinoma. A limited analysis of the KRAS
genotype did not provide a correlation with outcome in the
erlotinib-treated patients. An extensive series of Phase I–II
studies are underway evaluating other anti-EGFR targeting
agents with panitumumab, cetuximab and afatinib. Additional
studies currently in progress examine the role of MEK, Her-2
inhibition and anti-angiogenic agents such as sorafenib and
bevacizumab.
Other approaches to advanced cholangiocarcinoma include
regional treatment strategies, such as hepatic arterial infusion
(HAI) therapy and embolization therapies including both bland
embolization and transarterial chemoembolization (TACE) with
or without drug-eluting beads (DEBs), and yttrium-labelled
selective internal radiation therapy (SIRT). In a variety of studies
using TACE or DEB–TACE with various chemotherapeutic
approaches, median survival has ranged from 9 months to
30 months, but with significant toxicity in more than 20% of
patients.72–76 Outcomes of SIRT have been evaluated in limited
numbers of patients, and median survival has ranged from
9 months to 22 months.77–79 Encouraging data have been
observed in a single-institution Phase II trial of HAI of regional
floxuridine and dexamethasone,80 which showed a median sur-
vival of 29 months and a response rate of 47%. Further evalua-
tion is underway to examine the combination of systemic
therapy with HAI therapy (NCT01525069), as well as to conduct
an early evaluation in the adjuvant setting of resected ICC.
Clearly, a major limitation of the HAI approach is the limited
availability of oncologists experienced with its use outside select
institutions. Regional therapy remains an important treatment
option for patients with liver-only unresectable ICC, but current
recommendations are limited by a lack of prospective trials. Rig-
orous evaluation of these strategies in a clinical trial is essential.
To summarize, based on Phase III data, systemic therapy uti-
lizing cisplatin and gemcitabine represents the standard of care
for metastatic ICC. More intensive cytotoxic therapies (e.g.
FOLFIRINOX) are under study, as are a variety of targeted
agents, including anti-EGFR-based therapies. For select patients
in whom disease is confined to the liver, regional treatment
strategies are attractive options, but lack prospective compara-
tive data. Thus, recommendations for the type of regional ther-
apy should be based on institutional experience. Well-designed
prospective randomized trials evaluating regional strategies,
such as TACE, the use of DEBs, SIRT and others, are desper-
ately needed. These trials should be designed to provide insight
into the value of these therapies in comparison and in combi-
nation with systemic therapy, as well as to delineate the ideal
sequencing of treatment modalities. Finally, future trials in the
adjuvant and metastatic settings must take into account the
origin of the underlying tumour, as well as its histology.
Consensus statements
Adjuvant therapy
• There are no adequately powered, prospective randomized
Phase III trials that can provide definitive recommendations
for adjuvant therapy.
• There is no known benefit to adjuvant therapy in margin-
negative and node-negative ICC. Therefore, patients with
high-risk features (lymphovascular invasion, multicentricity
or satellitosis, large tumours) should be encouraged to enrol
in clinical trials.
• For resected margin-positive or node-positive ICC, systemic
therapy with either gemcitabine or 5-FU, or 5-FU-based
radiation should be considered. In patients with high-risk
features (satellitosis/multiple tumours, poor differentiation),
adjuvant therapy should also be considered.
• Randomized trials in the adjuvant setting evaluating gemcita-
bine, capecitabine, and gemcitabine and oxaliplatin com-
pared with observation will mature over the next few years.
Treatment of advanced ICC
• Cisplatin plus gemcitabine represents the standard-of-care,
front-line systemic therapy for metastatic ICC, based on
Phase III data, with an improvement in median survival of
3.6 months, compared with gemcitabine alone.
• Early data suggest a value for regional treatment of unresec-
table cholangiocarcinoma confined to the liver. Options
include embolization, chemoembolization, SIRT therapy and
HAI therapy, all of which can be considered as viable
options, given the lack of prospective comparative trials. The
choice of therapy is highly dependent on institutional experi-
ence.
• Genomic analyses of biliary cancers support the development
of targeted therapeutic interventions.
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